Barclays’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.57M | Sell |
243,776
-150,990
| -38% | -$2.41M | ﹤0.01% | 2021 |
|
|
2025
Q4 | $3.04M | Buy |
394,766
+85,614
| +28% | +$675K | ﹤0.01% | 2628 |
|
|
2025
Q3 | $2.28M | Sell |
309,152
-34,374
| -10% | -$176K | ﹤0.01% | 2799 |
|
|
2025
Q2 | $1.37M | Buy |
343,526
+260,295
| +313% | +$947K | ﹤0.01% | 3119 |
|
|
2025
Q1 | $265K | Sell |
83,231
-22,788
| -21% | -$107K | ﹤0.01% | 3895 |
|
|
2024
Q4 | $567K | Buy |
106,019
+106,018
| +10,601,800% | +$791K | ﹤0.01% | 3750 |
|
|
2024
Q3 | $5 | Hold |
1
| – | – | ﹤0.01% | 5248 |
|
|
2024
Q2 | $2 | Hold |
1
| – | – | ﹤0.01% | 4797 |
|
|
2024
Q1 | $2 | Hold |
1
| – | – | ﹤0.01% | 5033 |
|
|
2023
Q4 | $2 | Sell |
1
-13,681
| -100% | -$20K | ﹤0.01% | 5206 |
|
|
2023
Q3 | $20K | Buy |
13,682
+13,681
| +1,368,100% | +$28.9K | ﹤0.01% | 4180 |
|
|
2023
Q2 | $2 | Hold |
1
| – | – | ﹤0.01% | 4491 |
|
|
2023
Q1 | $1 | Hold |
1
| – | – | ﹤0.01% | 5053 |
|
|
2022
Q4 | $1 | Hold |
1
| – | – | ﹤0.01% | 5255 |
|
|
2022
Q3 | $0 | Sell |
1
-9,670
| -100% | -$9.22K | ﹤0.01% | 4843 |
|
|
2022
Q2 | $10K | Sell |
9,671
-1,425
| -13% | -$1.75K | ﹤0.01% | 4617 |
|
|
2022
Q1 | $18K | Sell |
11,096
-497
| -4% | -$910 | ﹤0.01% | 4468 |
|
|
2021
Q4 | $28K | Buy |
11,593
+11,592
| +1,159,200% | +$45K | ﹤0.01% | 3915 |
|
|
2021
Q3 | $0 | Sell |
1
-3
| -75% | -$9 | ﹤0.01% | 4774 |
|
|
2021
Q2 | $0 | Sell |
4
-533
| -99% | -$1.47K | ﹤0.01% | 4898 |
|
|
2021
Q1 | $2K | Buy |
537
+533
| +13,325% | +$1.93K | ﹤0.01% | 4554 |
|
|
2020
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 4924 |
|
|
2020
Q3 | $0 | Sell |
4
-2,205
| -100% | -$8.81K | ﹤0.01% | 5269 |
|
|
2020
Q2 | $6K | Buy |
2,209
+2,198
| +19,982% | +$6.5K | ﹤0.01% | 5375 |
|
|
2020
Q1 | $0 | Sell |
11
-12
| -52% | -$49 | ﹤0.01% | 6183 |
|
|
2019
Q4 | $0 | Sell |
23
-53
| -70% | -$185 | ﹤0.01% | 6406 |
|
|
2019
Q3 | $0 | Sell |
76
-13,556
| -99% | -$56.9K | ﹤0.01% | 6763 |
|
|
2019
Q2 | $51K | Buy |
13,632
+9,637
| +241% | +$37.8K | ﹤0.01% | 6078 |
|
|
2019
Q1 | $16K | Buy |
3,995
+3,852
| +2,694% | +$16.3K | ﹤0.01% | 6424 |
|
|
2018
Q4 | $0 | Sell |
143
-5,137
| -97% | -$35K | ﹤0.01% | 6989 |
|
|
2018
Q3 | $46K | Buy |
5,280
+4,260
| +418% | +$42.6K | ﹤0.01% | 6125 |
|
|
2018
Q2 | $12K | Sell |
1,020
-1,347
| -57% | -$15K | ﹤0.01% | 6450 |
|
|
2018
Q1 | $27K | Buy |
2,367
+773
| +48% | +$7.31K | ﹤0.01% | 6295 |
|
|
2017
Q4 | $17K | Buy |
1,594
+1,134
| +247% | +$14.5K | ﹤0.01% | 6349 |
|
|
2017
Q3 | $7K | Buy |
460
+421
| +1,079% | +$5.82K | ﹤0.01% | 6273 |
|
|
2017
Q2 | $0 | Sell |
39
-76
| -66% | -$811 | ﹤0.01% | 6674 |
|
|
2017
Q1 | $2K | Sell |
115
-45
| -28% | -$705 | ﹤0.01% | 6460 |
|
|
2016
Q4 | $2K | Buy |
160
+139
| +662% | +$2.11K | ﹤0.01% | 6335 |
|
|
2016
Q3 | $0 | Buy |
+21
| New | +$303 | ﹤0.01% | 6624 |
|
Other funds holding CRVS
O
ASP
VCM
VC
DTC
Barclays's CRVS Position: Q1 2026 in Review
Barclays reduced its Corvus Pharmaceuticals (CRVS) stake by 38% in Q1 2026, selling an estimated $2.41M and leaving 243,776 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2021.
Barclays first reported a position in CRVS in Q3 2016 and has held it in 39 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.
- Barclays held 243,776 shares of Corvus Pharmaceuticals worth $3.57M as of Q1 2026.
- Barclays sold 150,990 Corvus Pharmaceuticals shares in Q1 2026, an estimated $2.41M.
- Corvus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2021 holding.
- Barclays first reported a position in Corvus Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
- 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.